Joshua R. Kalna

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 3 papers. Top paper: “Kinome Reprogramming of G2/M Kinases and Repression of MYCN Contribute to Superior Efficacy of Lorlatinib in ALK-Driven Neuroblastoma”.

Kinome Reprogramming of G2/M Kinases and Repression of MYCN Contribute to Superior Efficacy of Lorlatinib in ALK-Driven Neuroblastoma

Molecular Cancer Therapeutics(2025)10.1158/1535-7163.mct-24-0684

N/A

0DataRank · unranked

4 citations

Michael P. East, Timothy J. Stuhlmiller, Gabriela M. Witek, Alvin Farrel, Steven Pastor +13 more

A humanized anaplastic lymphoma kinase (ALK)-directed antibody-drug conjugate with pyrrolobenzodiazepine payload demonstrates efficacy in ALK-expressing cancers

Nature Communications(2025)10.1038/s41467-025-62979-1

N/A

0DataRank · unranked

4 citations

Smita Matkar, Christina Acholla, Colleen E. Casey, Grant Li, Martina Mazzeschi +28 more

Kinome reprogramming of G2/M kinases and repression of MYCN contribute to superior efficacy of lorlatinib in ALK-driven neuroblastoma.

UNC Libraries(2025)10.17615/pbz0-mn14

N/A

0DataRank · unranked

0 citations

Mark Gerelus, Michael P. East, Alvin Farrel, Steven Pastor, John M. Maris +13 more